MyoKardia Inc (MYOK)

NASDAQ
224.91
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    224.52 - 225.00

MYOK Overview

Prev. Close
224.91
Day's Range
224.52-225
Revenue
-
Open
224.82
52 wk Range
93.07-225
EPS
-7.12
Volume
0
Market Cap
11.99B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
408,796
P/E Ratio
-
Beta
1.83
1-Year Change
0.87%
Shares Outstanding
53,322,904
Next Earnings Date
-
What is your sentiment on MyoKardia Inc?
or
Vote to see community's results!

MyoKardia Inc News

MyoKardia Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

MyoKardia Inc Company Profile

MyoKardia Inc Company Profile

Employees
318

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Read More
  • is it really worth to buy this price
    0
    • Hope this stock comes back to reality sooner than later!
      0
      • Hi Justin, you know that recommendations are only 1/3 of your decision how to invest own money. I check in Dec 2019 I've bought lot of NVAX sold with at very good profit but.... they jumped again. So, we still have a lot opportunities but ... as you know I'm from Poland so haven't full access to NYSE, NASDAQ and as a trader I'm very young.
        2
        • My MYOK money were working with; PLUG, VIVINT, ENPH ... so, Justin think twice or three times and who is on top?
          8
          • And I’ve owned NVAX the entire year. You made a terrible call on MYOK. Own it. :-)
            0
          • Don’t justify a bad call here. I will remember you.
            0
        • Escape, heading to $70.
          5
          • Yep, you look like a fool today. ;-)
            0
          • hahah thanks for selling your shares early
            0
          • HAHA! :-)
            0
        • After offering will go back to 20$
          3
          • what offering?
            0
          • Another liar and fool.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.